drugset / Trial / NCT03807843
Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
Phase 2
Completed
41 enrolled
Themis Bioscience GmbH
Walter Reed Army Institute of Research (WRAIR) · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
Safety and immunogenicity of the investigational V184 chikungunya vaccine will be tested in participants with history of chikungunya infection. Initially 21 to 50 year old participants will be enrolled; after favorable review of safety data, participants aged 51 to 65 will be enrolled.
Timeline
- Start
- 2019-07-16
- Primary completion
- 2021-05-13
- Completion
- 2021-05-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MV-CHIK | Vaccine | 500000 unknown | Intramuscular |